Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
Analytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
Services professionnels
Témoignages clients
Newsroom
Blog
Rapport mondial sur l'innovation
Glossaire
Webinaires et formations
Frontière
Communauté d'utilisateurs
Confiance et sécurité
PatentBench
LLM
Centre d'aide
Carrières
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport Explore the 2026 landscape of lithium battery electrolyte additive materials: film-forming agents, SEI compounds, flame retardants, and overcharge protection.
Article | Rapport Near memory computing architecture in 2026: PIM, CIM, and LIM technology clusters, key innovators, application domains, and strategic IP implications.
Article | Rapport SUMMIT Phase III trial: tirzepatide's dual GLP-1/GIP agonism improved KCCQ-CSS, 6-minute walk distance, and reduced HF events in obesity-related HFpEF. Full analysis.
Article | Rapport Explore the key engineering challenges of scalable solid-state lighting systems for horticulture and vertical farming, from thermal management to spectral tuning.
Article | Rapport Explore the 2026 landscape of lithium battery separator coating materials — ceramic, polymer, and functional coatings — with patent intelligence from PatSnap Eureka.
Article | Rapport How semaglutide's ESSENCE Phase III trial targets MASH histology beyond obesity—dual endpoints, GLP-1 liver mechanisms, and the competitive pipeline explained.
Article | Rapport No patent or literature data was returned for this edge AI inference query. Learn why evidence-based publication requires verified sources and how to proceed.
Article | Rapport Explore the 2026 bioelectronic neural interface materials landscape: key research directions, patent search strategies, and how to navigate this evolving field.
Article | Rapport Chromatin remodeling therapeutics 2026: SWI/SNF, PROTACs, CRISPR epigenome editing, and bromodomain inhibitors converge in oncology's fastest-growing IP landscape.
Article | Rapport Remibrutinib (LOU064) targets BTK in CSU mast cells. Explore Novartis's Phase III REMIX trials, omalizumab comparisons, and the oral BTK inhibitor opportunity.
Article | Rapport Key engineering considerations for high-reliability slip ring assemblies in wind turbine pitch control — materials, contact design, EMC, and standards guidance.
Article | Rapport Explore the 2026 EMI shielding materials landscape for 5G devices: key IPC codes, material categories, leading assignees, and how to run a full patent analysis.
Article | Rapport PIM vs active IMD in high-power RF antenna systems: key technical distinctions, design implications, and why patent data is essential for informed R&D decisions.
Article | Rapport Patent and research analysis of warehouse automation pick and place technology 2026: AMR fleets, RMFS, AI grasping, and human-robot collaboration trends.
Article | Rapport Spesolimab (Spevigo) blocks IL-36R to treat GPP and expanding IL-36 diseases. Explore Boehringer Ingelheim's Phase III pipeline and what it means for dermatology R&D.